COMMUNIQUÉS West-GlobeNewswire

Turkish Airlines Sports Club Women’s Volleyball Team Completes Pre-Season Health Checks at Medicana
31/07/2026
The renewed healthcare sponsorship brings together one of Turkiye’s leading volleyball teams and Medicana Health Group’s multidisciplinary expertise in athlete health and preventive care ISTANBUL, July 31, 2026 (GLOBE [...]
Moleculin Announces Pricing of $9.3 Million Public Offering
31/07/2026
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of [...]
Human Appeal USA Announces "The Biggest Comedy Show" 2026 Tour: A 25-City Nationwide Event Where Every Laugh Gives Back to Global Humanitarian Relief
31/07/2026
MISSION VIEJO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Human Appeal USA, a humanitarian nonprofit, announced the Biggest Comedy Show 2026 tour, which will launch this fall across 25 U.S. cities. The tour unites [...]
EUROAPI_Mise à disposition du Rapport Financier Semestriel 2026
31/07/2026
Communiqué de presse Paris, le 31 juillet 2026 Mise à disposition du Rapport financier semestriel 2026 EUROAPI a mis en ligne ce jour ses Etats Financiers semestriels consolidés condensés 2026 pour la période close le [...]
EUROAPI_Availability of 2026 Half-year results financial report
31/07/2026
Press Release Paris, 31 July 2026 Availability of 2026 Half-Year Financial Report EUROAPI posted today its 2026 condensed Half Year Consolidated Financial Statements for the six months ended June 30, 2026. This document [...]
Italfarmaco Announces Managed Entry Agreement in Georgia for Givinostat as Treatment for Patients with Duchenne Muscular Dystrophy
31/07/2026
MILAN, Italy, July 31, 2026 – Italfarmaco S.p.A. today announced a managed entry agreement with the Georgian Ministry of Health for givinostat (Duvyzat ® ) as a treatment for patients with Duchenne muscular dystrophy ( [...]
Vireo Growth Inc. Announces a Four-Deal Transaction to Establish Presence in Ohio
31/07/2026
Further Expands Vireo's National Platform, Creating One of the Industry's Broadest State Footprints MINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company [...]
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
31/07/2026
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody [...]
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
31/07/2026
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 (GLOBE NEWSWIRE [...]
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
31/07/2026
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
31/07/2026
BOCA RATON, Fla., July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that on July 30, 2026, it [...]
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
31/07/2026
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or [...]
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
31/07/2026
Management to host conference call and webcast at 4:30 pm ET on that day BOCA RATON, Fla, July 31, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on [...]
Radiopharm Theranostics Reports Business Update
31/07/2026
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial of [...]
Ocugen to Participate in Upcoming August Investor Conferences
31/07/2026
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
31/07/2026
Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, [...]
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
31/07/2026
Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance personalized medicine in women's health PHILADELPHIA, July 31, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]
J-Star Holding Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
31/07/2026
TAICHUNG CITY, Taiwan, July 31, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), today announced that it has received a written decision from the Nasdaq Hearings Panel [...]
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
31/07/2026
GAITHERSBURG, Md., July 31, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2026 [...]

Pages